TALACEN
LOE ApproachingNDAORALTABLET
Approved
Sep 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALACEN is an oral tablet small-molecule NDA approved in 1982 by Sanofi. The indication and mechanism of action are unknown based on available data. This product represents a legacy small-molecule asset with significant market history.
LOE Approaching
Moderate competitive pressure (30/100) suggests TALACEN maintains market presence, but LOE approach indicates shrinking team and transition planning becoming critical.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TALACEN has zero linked job openings and is approaching loss of exclusivity, making it a declining career opportunity. Career growth on this product will be limited; roles will focus on managed decline and portfolio transition.
Brand ManagerField Sales Representative
Worked on TALACEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.